Jean-Pierre Delord Selected Research

N- (2,3- dihydroxypropyl)- 1- ((2- fluoro- 4- iodophenyl)amino)isonicotinamide

1/2021	Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
1/2021	Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean-Pierre Delord Research Topics

Disease

77	Neoplasms (Cancer) 01/2024 - 06/2006
17	Squamous Cell Carcinoma of Head and Neck 03/2024 - 12/2007
12	Carcinoma (Carcinomatosis) 02/2023 - 09/2010
11	Colorectal Neoplasms (Colorectal Cancer) 12/2023 - 02/2003
11	Disease Progression 10/2023 - 03/2012
8	Ovarian Neoplasms (Ovarian Cancer) 10/2023 - 01/2014
7	Head and Neck Neoplasms (Head and Neck Cancer) 12/2023 - 09/2010
7	Melanoma (Melanoma, Malignant) 01/2021 - 12/2015
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2020 - 03/2008
7	Breast Neoplasms (Breast Cancer) 01/2020 - 08/2007
6	Neoplasm Metastasis (Metastasis) 01/2023 - 06/2015
5	Febrile Neutropenia 03/2024 - 10/2013
5	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 10/2023 - 01/2017
4	Asthenia 04/2024 - 11/2011
4	Nausea 04/2024 - 11/2011
4	Fatigue 10/2023 - 01/2018
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 05/2013
3	Exanthema (Rash) 04/2024 - 12/2018
3	Vomiting 04/2024 - 12/2018
3	Prostatic Neoplasms (Prostate Cancer) 05/2023 - 10/2018
3	Mesothelioma 11/2020 - 01/2019
3	Diarrhea 12/2018 - 11/2011
2	Fever (Fevers) 04/2024 - 11/2011
2	Hepatocellular Carcinoma (Hepatoma) 04/2024 - 06/2022
2	Pruritus (Itching) 04/2024 - 08/2015
2	Deglutition Disorders (Dysphagia) 03/2024 - 03/2015
2	Acute Kidney Injury (Acute Renal Failure) 03/2024 - 08/2018
2	Sepsis (Septicemia) 03/2024 - 10/2013
2	Stomatitis 03/2024 - 12/2018
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2024 - 05/2015
2	Constipation 10/2023 - 01/2018
2	Renal Cell Carcinoma (Grawitz Tumor) 02/2023 - 11/2017
2	Glioblastoma (Glioblastoma Multiforme) 01/2023 - 02/2019
2	Hypotension (Low Blood Pressure) 11/2020 - 10/2013
2	Thrombocytopenia (Thrombopenia) 12/2018 - 10/2018

Drug/Important Bio-Agent (IBA)

12	Cetuximab (Erbitux)FDA Link 11/2023 - 06/2006
10	pembrolizumabIBA 03/2024 - 01/2018
9	Monoclonal AntibodiesIBA 01/2022 - 06/2006
8	Biomarkers (Surrogate Marker)IBA 12/2023 - 09/2010
8	PlatinumIBA 11/2023 - 03/2008
8	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 02/2009
7	LigandsIBA 11/2023 - 01/2018
7	Immune Checkpoint InhibitorsIBA 01/2023 - 12/2015
6	ErbB Receptors (EGF Receptor)IBA 12/2023 - 06/2006
6	Proteins (Proteins, Gene)FDA Link 01/2023 - 09/2010
5	AfatinibIBA 12/2023 - 01/2018
5	atezolizumabIBA 12/2023 - 01/2019
5	NivolumabIBA 02/2023 - 11/2019
5	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 02/2003
5	Erlotinib Hydrochloride (CP 358,774)FDA Link 06/2013 - 12/2007
4	durvalumabIBA 01/2024 - 01/2019
4	Tyrosine Kinase InhibitorsIBA 01/2024 - 02/2015
4	PM 01183IBA 10/2023 - 01/2020
4	B7-H1 AntigenIBA 01/2023 - 10/2019
4	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 01/2011
4	emactuzumabIBA 01/2022 - 06/2014
4	CreatinineIBA 12/2020 - 01/2018
3	spartalizumabIBA 04/2024 - 10/2020
3	AlpelisibIBA 11/2023 - 01/2017
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 10/2023 - 10/2020
3	Alanine Transaminase (SGPT)IBA 10/2023 - 07/2011
3	AcidsIBA 01/2023 - 02/2003
3	CytokinesIBA 11/2022 - 03/2014
3	Carboplatin (JM8)FDA LinkGeneric 09/2022 - 01/2016
3	Docetaxel (Taxotere)FDA Link 01/2021 - 01/2017
3	AntibodiesIBA 01/2020 - 01/2019
3	Trastuzumab (Herceptin)FDA Link 12/2018 - 06/2011
3	Vinorelbine (Navelbine)FDA LinkGeneric 01/2018 - 02/2009
3	Antineoplastic Agents (Antineoplastics)IBA 01/2016 - 05/2013
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 03/2012 - 02/2003
2	capmatinibIBA 04/2024 - 12/2020
2	TabletsIBA 11/2023 - 01/2020
2	Transaminases (Aminotransferases)IBA 10/2023 - 01/2017
2	IpilimumabIBA 02/2023 - 01/2021
2	olaparibIBA 01/2023 - 01/2020
2	avelumabIBA 01/2023 - 01/2019
2	IntegrinsIBA 01/2023 - 01/2018
2	Paclitaxel (Taxol)FDA LinkGeneric 09/2022 - 08/2018
2	Everolimus FDA Link 09/2022 - 11/2017
2	Neoplasm Antigens (Tumor Antigens)IBA 07/2022 - 01/2021
2	Oncogene Proteins (Oncogene Protein)IBA 01/2022 - 01/2016
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 02/2021 - 01/2021
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2021 - 01/2021
2	Infliximab (Remicade)FDA Link 01/2021 - 11/2019
2	N- (2,3- dihydroxypropyl)- 1- ((2- fluoro- 4- iodophenyl)amino)isonicotinamideIBA 01/2021 - 01/2021
2	Tumor Necrosis Factor InhibitorsIBA 01/2021 - 11/2019
2	Inhibitor of Apoptosis ProteinsIBA 12/2020 - 01/2020
2	Macrophage Colony-Stimulating FactorIBA 10/2020 - 08/2015
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020 - 11/2019
2	F14512IBA 01/2019 - 01/2016
2	PolyaminesIBA 01/2019 - 01/2016
2	Pemetrexed (MTA)FDA Link 01/2019 - 01/2017

Therapy/Procedure

34	Therapeutics 03/2024 - 08/2007
20	Drug Therapy (Chemotherapy) 10/2023 - 08/2007
10	Immunotherapy 11/2023 - 05/2014
8	Chemoradiotherapy 03/2024 - 01/2018
4	Aftercare (After-Treatment) 01/2023 - 11/2011
3	Intravenous Infusions 12/2023 - 01/2020
3	Radiotherapy 05/2019 - 12/2015
2	Castration 05/2023 - 01/2021